Actively Recruiting

Age: 18Years +
All Genders
NCT06713850

Angioplasty With Shockwave IVL Catheter System in Femoropopliteal Lesions

Led by Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Updated on 2024-12-03

130

Participants Needed

1

Research Sites

204 weeks

Total Duration

On this page

Sponsors

L

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Lead Sponsor

S

Shanghai Zhongshan Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

There is a lack of prospective observational studies of shockwave balloons in the treatment of moderate-to-severe calcification of the femoral popliteal artery at the international level. Therefore, in this study, we wish to set up a real-world study of shockwave balloon in the treatment of moderate-to-severe calcification to investigate the real-world efficacy of shockwave balloon in the treatment of moderate-to-severe calcified lesions.

CONDITIONS

Official Title

Angioplasty With Shockwave IVL Catheter System in Femoropopliteal Lesions

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Rutherford Classification 2-5
  • More than 70% narrowing or blockage of the femoropopliteal artery confirmed by imaging
  • One healthy patent outflow tract below the knee continuing to a patent outflow tract below the ankle
  • Understands the study purpose, voluntarily consents, and agrees to follow-up
  • Guidewire can pass through the lesion
  • Life expectancy greater than 24 months
  • Moderate to severe calcified lesions confirmed by imaging
  • Patients receiving treatment in both legs may enroll based on treatment timing
  • For combined aortoiliac artery lesions, prior successful revascularization with less than 50% residual narrowing
Not Eligible

You will not qualify if you...

  • Stroke, cerebral hemorrhage, gastrointestinal bleeding, or heart attack within 3 months before enrollment
  • Known allergy to heparin, aspirin, other antiplatelet drugs, or contrast agents
  • Use of interfering medications or special vascular devices within past 3 months
  • Pregnant or breastfeeding women
  • Unable or unwilling to participate in the trial
  • Diagnosis of Berger's disease
  • Previous arterial bypass surgery on the treated leg

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Actively Recruiting

Loading map...

Research Team

Z

Zibo Feng, MD

CONTACT

Y

Ye Du, DM

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here